LATEST NEWS

Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.